Evidence map›Paper›PMID 42746031›Full record

ArticleFrontiers in pharmacology2026

Pharmacokinetics, mass balance, and metabolism of [

Sheng Ma, Xintong Huang, Shu Yan, Haonan Liu, Hua Zhang, Yifan Zhang, Weiwei Cui, Cungang Ding, Xingxing Diao, Liyan Miao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sheng Ma *Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China.
Xintong Huang *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Shu YanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Haonan LiuTianjin University of Traditional Chinese Medicine, Tianjin, China.
Hua ZhangDepartment of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yifan ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Weiwei CuiShanghai Pharmaceuticals Holding Co., Ltd., Shanghai, China.
Cungang DingShanghai Pharmaceuticals Holding Co., Ltd., Shanghai, China.
Xingxing DiaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Liyan MiaoDepartment of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: SPH3127 (Sitokiren), a novel direct renin inhibitor used to treat hypertension, is currently approved for marketing in China. The primary objective of this study was to determine the pharmacokinetics, mass balance, and biotransformation of [ Methods: The absorption, metabolism, and excretion of SPH3127 were characterised via isotope labeling technology in six healthy Chinese male subjects after receiving a single 100 mg oral dose of [ Results: SPH3127 was rapidly absorbed, with median T Conclusion: SPH3127 showed favourable pharmacokinetic characteristics and safety profiles in this study. SPH3127 was rapidly absorbed and extensively metabolized in humans. The main excretion route of SPH3127 and its metabolites was through urine and feces. Clinical Trial Registration: http://www.chinadrugtrials.org.cn/, identifier CTR20222187.

Indexed as

[14C]SPH3127drug metabolismmass balancepharmacokineticsradioactivityrenin inhibitor

Identifiers

PMID42746031
PMCPMC13574930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.